OBJECTIVES:  To develop a budget impact analysis from the perspective of the Colombian state, related to pazopanib-Everolimus use in first and second line of treatment, respectively, compared with pazopanib-Axitinib, sunitinib-everolimus and sunitinib-axitinib in patients with metastatic renal cell carcinoma. METHODS:  A three years analysis was designed, with the shares of the possible combinations of technologies in first-line (pazopanib and sunitinib) with second-line (everolimus and axitinib), which were consulted clinical experts to evaluate the combinations in the current scenario of the four treatment options. The shares in the new scenario, starting in the first year with increasing share of the main combination of analysis (Pazopanib-everolimus), which comes from 21.95% to 30% in the first year, with progressive increases up to 40 % in the third year, and the other 60% spread among the other three combinations of technologies. The costs are showed in United States dollars, using current exchange rate to Colombian pesos RESULTS:  According to the base case analyzed in terms of total cumulative impact in Colombian pesos and impact on Capitation payment unit, the use of pazopanib-everolimus in first and second line of treatment respectively generates savings of US $0.1016 at third year, representing a -0.0501% impact on capitation payment unit of 2016. CONCLUSIONS:  The use of pazopanib-Everolimus is an option that turns out to be thrifty from the first year for the third payer, as well as an impact with a negative sign on the capitation payment unit from the first to the third year as a result of the comparison of the impact between current and new scenario.